/stocks — the workspaceLOADING
All PALISEC filings, by type → · Earnings date & implied move · Search inside filings
PALISADE BIO, INC. (PALI) is a biological products, (no diagnostic substances) company. Piotroski F-Score 1/7. 10 insider Form 4 filings in the last 90 days. Next earnings projected around 2027-05-11 from PALI's year-over-year reporting pattern (not yet company-confirmed). Fundamentals from SEC filings; prices are end-of-day.
What’s behind PALI’s latest move — the size, how unusual the volume is, and the catalyst on the tape, explained and cited to the source.
EOD daily bars · delayed, not real-time · data: DatabentoCharting by TradingView Lightweight Charts™
FY ending 2024-12-31 vs 2023-12-31. original 1968 formula; calibrated on manufacturers, read financials/REITs with care
Estimates, not targets. The DCF treats free cash flow as cash flow to equity and divides by shares (the common retail shortcut — it skips net debt and a full WACC), so it’s a sanity-check, not a valuation opinion. All inputs are from PALI’s SEC filings; change any assumption above and the numbers update live. Educational only — not investment advice.
A plain-English read on PALI plus an auto-SWOT — built from PALI's SEC filings and market data, every point cited, nothing invented. Educational, not investment advice.
Four AI analysts — a bull, a bear, a risk manager, and a PM — debate PALI using only the SEC-filing and market facts below. Every point cites its evidence; nothing is invented. This is educational research, not investment advice.
Educational only — not financial advice. Data from SEC EDGAR public filings; no live market data is shown. Figures reflect the company's own reported XBRL facts and may lag.
XBRL company facts, SEC EDGAR. TTM = last four reported quarters. Valuation ratios arrive with a price source — we don't fake quotes.
Has PALI been issuing shares? Offering history →
↓ Download the fiscal-year statement table (XLSX) · revenue, income, EPS, cash flow, balance sheet · from SEC XBRL, dated
No tracked institution reported a position in PALI in the latest 13F round.
No lawmaker has disclosed a trade in PALI under the STOCK Act.
| Baltera Robert Jr.Director | BUY | $89K | view → |
| Finley John DavidCEO, CFO | SELL | $303K | view → |
| Jones Mitchell LawrenceChief Medical Officer | SELL | $107K | view → |
| Baltera Robert Jr.Director | BUY | $102K | view → |
| Baltera Robert Jr.Director | BUY | $59K | view → |
Projected from PALI's own SEC 8-K filing history — the year-over-year reporting pattern (about 47% land the exact day, about 91% within a week, measured across 4,713 past reports). No analyst estimates and nothing invented, and every confirmed date links to the source it came from, so you can check it yourself. It upgrades the momentPALI files or announces.
| Reported | Close-to-close |
|---|---|
| 2026-08-10 | +1.4% |
| 2026-05-12 | -3.6% |
Earnings dates are the company's 8-K Item 2.02 filings (SEC). Reactions from Databento EOD.
From SEC Form 4 and 13F filings. Both are backward-looking disclosures on different reporting clocks, and neither predicts price. Educational information only — not investment advice.